NDA for Research and Development UK: Protecting Innovation Before It's Patented

Research and development sits at the intersection of two legal frameworks that pull in opposite directions. Patent law rewards disclosure — a granted patent is a published monopoly. Trade secret law rewards secrecy — protection lasts only while the information remains confidential. In the window between generating an R&D result and deciding what to do with it, the non-disclosure agreement (NDA) is the tool that keeps both options open.

Why R&D needs a different kind of NDA

A standard commercial NDA — adequate for sharing pricing, a customer list, or a business plan — is often insufficient for R&D. Research information has specific features that require deliberate drafting.

First, the confidential information definition must be precise enough to cover what is actually shared: experimental protocols, data sets, negative results (which are commercially valuable even when not published), software source code, and manufacturing know-how. A generic definition of confidential information may leave critical categories unprotected.

Second, R&D results are often on a path to patent filing. An NDA that allows disclosure to third parties — even with a confidentiality obligation on those third parties — can create novelty problems if those disclosures are deemed public for patent law purposes. The NDA must restrict onward disclosure tightly.

Third, publication is a normal part of academic R&D. Industry partners need a contractual right to review and delay proposed publications before they go public, to enable patent filing during the review window. Without this, the academic partner's publication obligation and the company's novelty interest are in direct conflict.

The patent novelty problem

The single most important reason an R&D NDA must be in place before any technical disclosure is the patent novelty requirement.

Under the Patents Act 1977 and the European Patent Convention, an invention must be novel — it must not have been made available to the public anywhere in the world before the filing date of the patent application. A disclosure to a single person outside the inventing team, without a binding confidentiality obligation, can count as prior art that destroys novelty and prevents a valid patent from being granted.

An NDA does not extend the novelty window — you still need to file before disclosing publicly. What an NDA does is keep disclosures private, so that they do not count as prior art. A company partner briefing a university on a technical problem under a mutual NDA does not make that information public. A conference presentation, an unprotected email chain, or a casual meeting without one does.

R&D NDA scenarios

Industry-academia partnerships

The most complex R&D NDA situation in the UK is the industry-academia partnership — where a company and a university (or other research institution) collaborate on a funded innovation project.

Both parties bring background IP — existing knowledge, software, methods and materials — and both create foreground IP during the collaboration. The academic partner typically has a contractual obligation with its funder (Research England, UKRI, Innovate UK) to publish results; the company partner typically wants to delay publication until a patent application has been filed.

The standard structure is: a mutual NDA at the start to enable early discussions, followed by a formal collaboration agreement that governs background IP licences, foreground IP ownership, publication approval, cost sharing, and commercialisation. The NDA is a bridge to that agreement, not a substitute for it.

Trade secrets: protecting what you choose not to patent

Not all R&D results are best protected by a patent. Patenting requires public disclosure of the invention in the patent specification. If a manufacturing process, formulation or algorithm is genuinely difficult to reverse-engineer from the product, keeping it secret under a trade secret regime may provide stronger and longer-lasting protection than a 20-year patent.

The Trade Secrets (Enforcement, etc.) Regulations 2018 give UK law a coherent framework for trade secret protection: information qualifies as a trade secret if it has commercial value, is not generally known, and the owner takes reasonable steps to keep it confidential. An NDA is the primary reasonable step — it is the contractual evidence that you treat the information as secret.

Unlike patents, trade secret protection has no expiry date, no registration requirement, and no public disclosure. The protection lasts for as long as the information remains genuinely confidential. The corresponding risk is that if the information is independently discovered, or leaked despite the NDA, the protection is lost.

IP assignment in R&D commissioning

When one business commissions R&D from an external laboratory, contract research organisation or specialist consultancy — rather than collaborating as joint parties — the IP position is different. The contractor will typically own the IP it creates by default, in the same way a freelance designer owns their work.

An NDA with IP assignment is the appropriate document for this relationship. It combines the confidentiality obligation (the contractor cannot disclose the commission, the brief or the results) with a clause assigning ownership of all results, inventions and know-how generated during the engagement to the commissioning business on creation.

Without the assignment, the commissioning business may have a licence to use the results but will not own them. This creates problems if the business later seeks to patent the results, licence them to a third party, or sell the business — in each case the buyer or licensor will want clear title to the IP, which requires the contractor's cooperation to establish.